March 13 Amgen Inc said on Monday its
injection Repatha significantly reduced the need for patients to
undergo a procedure to reduce bad cholesterol, according to the
findings of a late-stage study.
The drug, like Regeneron Inc and Sanofi SA's
Praluent, belongs to a class of medicines called PCSK9
inhibitors that were approved on their ability to dramatically
lower "bad" LDL cholesterol.
Besides taking drugs, cholesterol patients often undergo a
procedure called apheresis, which is as invasive as dialysis and
involves using a machine that removes bad cholesterol over a
period of between one and three hours, Amgen said.
(Reporting by Natalie Grover in Bengaluru; Editing by Savio